Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after Olaparib treatment

2024-518069-89-00 Therapeutic exploratory (Phase II) Ongoing, recruitment ended

Start 3 Feb 2020 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 9 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruitment ended
Participants planned 230
Countries 1
Sites 9

Patients with solid cancers

Key facts

Sponsor
Centr Georges Francois Leclerc
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
3 Feb 2020 → ongoing
Decision date (initial)
2024-10-15
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-518069-89-00
EudraCT number
2018-002971-17
ClinicalTrials.gov
NCT04169841

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with solid cancers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centr Georges Francois Leclerc

Sponsor organisation
Centr Georges Francois Leclerc
Address
1 Rue Professeur Marion
City
Dijon
Postcode
21000
Country
France

Scientific contact point

Organisation
Centr Georges Francois Leclerc
Contact name
François GHIRINGHELLI

Public contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Emilie REDERSTORFF

Locations

1 EU/EEA country · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 230 9
Rest of world 0

Investigational sites

France

9 sites · Ongoing, recruitment ended
Centr Georges Francois Leclerc
Oncology, 1 Rue Professeur Marion, 21000, Dijon
IHFB Cognacq Jay
Oncology, 4 Rue Kleber, 92300, Levallois-Perret
Institut Bergonie
Oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Centre Oscar Lambret
Oncology, 3 Rue Frederic Combemale, 59000, Lille
Centre Hospitalier Universitaire De Dijon
HGE, 14 Rue Paul Gaffarel, 21000, Dijon
Centre Leon Berard
Oncology, 28 Rue Laennec, 69008, Lyon
Centre Hospitalier Universitaire De Poitiers
Oncology, 2 Rue De La Miletrie, 86000, Poitiers
CHU Besancon
Oncology, 3 Boulevard Alexander Fleming, Cs 81816, Besancon Cedex
Hospices Civils De Lyon
Oncology, 3 Quai Des Celestins, Bp 2251, Lyon Cedex 02

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2020-02-03 2020-02-03 2023-06-30

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-26 France Acceptable
2024-10-11
2024-10-15
2 SUBSTANTIAL MODIFICATION SM-1 2025-11-05 France Acceptable
2025-12-17
2026-01-07